News
Interview on Czech Radio at 6:20 a.m. with neurologist Prof. MUDr. David Školoudík, Ph.D., FESO, FEAN, and David Maršálek, CEO and Founder of H2 Global Group, discussing molecular hydrogen and the first clinical study of its kind in the Czech Republic.
A unique experiment is being prepared in Ostrava. For the first time in the Czech Republic, physicians will study the...
“Staying Forever Young”: H2 Global Group Brings a Hydrogen Standard to the Longevity Sector
Prague, 3 December 2025 (PROTEXT) – The longevity market is experiencing a global boom. More and more people are...
H2 Global Group – Press Conference at ČTK
Molecular Hydrogen and Dementia Prevention: Czech Research Heads into Its First Clinical Study Today, on 12 November...
H2 Global Group – Our Story
It has been nearly 14 years since David Maršálek happened to meet Professor Dušan Miljković in the USA – the man who...
“Alzheimer’s dementia: a breakthrough gentle Czech solution turns a problem into an opportunity. And investors don’t want to miss out.”
Precisely in this field comes news from the Czech Republic with the potential to place the country on the map of world...
Czech Breakthrough in Medicine: H2 Global Group Receives Regulatory Approval for Hydrogen Clinical Study — New Era in Alzheimer’s Therapy Begins
European innovation leader H₂ Global Group today announced that its subsidiary H₂ Medical Technologies has received...





